Robert A. Bradway is Amgen’s chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.

Prior to joining Amgen, he was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.

He served as the chairman of the CEO Roundtable on Cancer from 2015 up until 2022. Amgen has been a member of the CEO Roundtable on Cancer since 2014, the same year the company earned Gold Standard Accreditation in the US. Amgen earned Gold Standard accreditation in China in 2017. The company also has been a data contributor to Project Data Sphere since 2015.

He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is a member of the American Heart Association CEO Roundtable on Cancer, which is helping the Association meet its goal of improving the cardiovascular health of all Americans. He is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors. He also sits on the board of directors for both Boeing and the Norfolk Southern Railway Corporation.

Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.